CoCensys pushes into psychiatrics

CoCensys pushes into psychiatrics In a move that expands its CNS therapeutics portfolio from psychiatry into neurology, CoCensys Inc. struck a two-part collaboration with Warner-Lambert Co. and its Parke-Davis division.

COCN will co-promote Parke-Davis’ Cognex Alzheimer’s drug to U.S. neurologists. Parke-Davis retains rights to market Cognex to all other physician groups in the U.S., as well as in all other markets worldwide. Although Cognex sales have been slow — the drug posted $50 million in 1994 sales — COCN President and CEO Daniel Korpolinski said he believes the market can be expanded significantly, as Cognex is the only treatment for the disease...